Trial Profile
Phase II Study of Anti-CD20 Antibody Therapy Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular and Diffuse Large B-Cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary) ; Pembrolizumab (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Therapeutic Use
- 01 Feb 2024 Planned End Date changed from 30 Jan 2026 to 19 Dec 2025.
- 06 Jul 2023 Planned End Date changed from 30 Jul 2024 to 30 Jan 2026.
- 02 Feb 2023 Planned End Date changed from 16 Jul 2024 to 30 Jul 2024.